secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001104659-26-050318
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud

Arcellx completes acquisition by Gilead Sciences subsidiary for $115 per share plus CVR
--------------------------------------------------------------------------------

- Tender offer expired with 38,795,604 shares tendered, representing ~77.2% of outstanding shares.
- Merger consideration: $115 per share cash plus one contingent value right of up to $5 per CVR payable by 2030.
- Aggregate funds used by Gilead to consummate the offer and merger were approximately $7.1 billion.
- Arcellx requested delisting from Nasdaq and intends to terminate SEC registration.
- All directors and officers resigned; new directors and officers appointed from Gilead subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000110465926050318/0001104659-26-050318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000110465926050318/tm2612746d7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-050318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer